lithionit 83 mg
karo pharma ab (1) - litiumsulfat - depottablett - 83 mg
leukeran 2 mg
aspen pharma trading limited - klorambucil - tablett, filmdrasjert - 2 mg
niferex 100 mg
ucb pharma gmbh - jern(ii)glysinsulfat - enterokapsel, hard - 100 mg
prascend 1 mg
boehringer ingelheim vetmedica gmbh - pergolidmesilat - tablett - 1 mg
sinemet 12,5/50 12.5 mg / 50 mg
n.v. organon - kloosterstraat - karbidopa / levodopa - tablett - 12.5 mg / 50 mg
sinemet 25/100 25 mg / 100 mg
n.v. organon - kloosterstraat - karbidopa / levodopa - tablett - 25 mg / 100 mg
sinemet depot mite 25 mg / 100 mg
n.v. organon - kloosterstraat - karbidopa / levodopa - depottablett - 25 mg / 100 mg
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Øyemidler - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
carmustine macure 100 mg
macure pharma aps - karmustin - pulver og væske til konsentrat til infusjonsvæske, oppløsning - 100 mg